TRANXENOGEN, INC.

Appointment of New CEO

TranXenoGen, Inc. ("TranXenoGen" or the "Company"), the US based avian transgenic technology company listed on AIM, announces that George Uveges has joined the Company as President, Chief Executive Officer and director effective today.

Mr Uveges brings to TranXenoGen management experience in the biotechnology and healthcare industries, as well as a range of other commercial environments.

Most recently he was Chief Operating Officer of Biosource International, Inc., a $32 million turnover NASDAQ company, where he was responsible for managing three of its US subsidiaries and its European subsidiary as well as various administrative and manufacturing functions. Prior to this he was Senior Vice President and Chief Financial Officer with NEN Life Sciences, Inc., a $125 million turnover company, which was acquired from DuPont in an LBO in July 1997 and sold to Perkin Elmer in July 2000. Previously he has also held the positions of Chief Financial Officer of Gelman Sciences Inc., Chief Financial Officer of G.I. Plastek and Treasurer and Chief Accounting Officer with Invacare Corporation. Following his degree in 1970 he became a Certified Public Accountant (CPA) spending 13 years with Ernst & Young, during which time he also gained his MBA.

Commenting on Mr Uveges appointment, Dr Kim Tan, Chairman, commented:

"We are delighted to have George join us. He has extensive experience in public and private companies and has delivered on challenging business plans, achieving growth both through organic expansion and mergers and acquisitions. He is the ideal person to take TranXenoGen to the next stage of its development. In particular, George has significant board level experience with companies providing services to the life science industry as well as a very strong commercial and financial background."

Mr Uveges added:

"I am excited to start working with TranXenoGen and look forward to meeting with the Company’s investors in the near future. I believe that the Company is financially strong and it has a very sound technology platform, both in its science and its team. I am looking forward to the opportunity of meeting the industry needs and addressing the pharmaceutical industry’s protein supply constraints."

Pursuant to Rule 15 and paragraph (f) of Schedule 2 of the AIM Rules, the following information is announced in respect of George Uveges:
  1. His full name is: George Uveges, aged 53.
  2. Mr Uveges has not held within the past 5 years and does not hold any directorships.
  3. Mr Uveges has not held within the past 5 years and does not hold any partnerships.
  4. Mr Uveges has no/not:
    1. any unspent convictions in relation to indictable offenses;
    2. had any bankruptcy order made against him or entered into any individual voluntary arrangement;
    3. been a director of a company which has been placed into receivership, compulsory liquidation, creditors’ voluntary liquidation, administration or which has entered into any company voluntary arrangements or any composition or arrangement with its creditors generally or any class of its creditors, at the time of or within twelve months preceding such events;
    4. been a partner of any partnership which has been put into compulsory liquidation, administration or entered into partnership voluntary arrangements, at the time of or within twelve months preceding such events;
    5. had a receivership of any assets of such Director or of a partnership where he was a partner at the time of or within the twelve months preceding such event; or
    6. been publicly criticised by statutory regulatory authorities (including recognising professional bodies) nor has such Director ever been disqualified by a court from acting as a director of a company or from acting in the management or conduct of the affairs of the company.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from the statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risks associated with the inherent uncertainty of product research, risks of protecting proprietary rights and competition.


22 October 2001
ENQUIRIES:

TranXenoGen, Inc (www.tranxenogen.com)
Dr Kim Tan +44 1483 572911
George Uveges +1 508 842 5036

College Hill +44 20 7457 2020
Michael Padley
Nicholas Nelson

West LB Panmure Limited +44 20 7020 4000
Ronald Openshaw

Notes to Editors

TranXenoGen, Inc. (symbol: TXN.L) is a publicly listed company on the Alternative Investment Market of the London Stock Exchange. The company specializes in the application of second-generation transgenic technology to the production of complex high-volume human therapeutic proteins in the egg albumin fraction of transgenic chicken eggs.